{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024450","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.182569+00:00","generated_at":"2026-05-16T18:14:11.319721+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir-1 kills aggressive human leukemia cells in vitro; expands oncology profile into blood cancers","bullets":["Telomir-1 produced dose-dependent reduction in viability of human HL60 leukemia cells (aggressive AML model).","Leukemia cells depend on intracellular iron; Telomir-1 lowers intracellular Fe²⁺ more potently than DFO.","Prior research shows Telomir-1 reduces abnormal DNA methylation of tumor-suppressor genes and inhibits KDM histone demethylases.","Findings add to previously reported activity against triple-negative breast, pancreatic, and prostate cancer models."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024450","json":"https://secwatch.observer/filing/0001493152-25-024450.json","markdown":"https://secwatch.observer/filing/0001493152-25-024450.md","text":"https://secwatch.observer/filing/0001493152-25-024450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225024450/0001493152-25-024450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225024450/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:14:11.319721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}